Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOnconetix Inc

Onconetix Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
6.95 USD 1.46 ( 26.59%)
Last update at 2026-11-06T21:02:00Z
VOLUME
698818
Market Cap
2.89M

Momentum Score

…

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.62
Low
7.82
High
52 Week Price Range
0.59
Low
209.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Publicly available disclosures for Onconetix Inc (NASDAQ: ONCO) are limited, and the company's core business activities and product pipeline are not clearly described in widely accessible sources. Potential long-term growth may depend on progress in any clinical or product development, strategic partnerships, and successful capital raises, which could support scaling if the company advances programs or secures collaborations.

The most important investment risk is the combination of limited transparency and typical early-stage biotech exposures—material financing needs, regulatory and clinical development uncertainty, and execution risk—that could significantly affect prospects.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
5.49
Dividend Yield
-
Revenue TTM
0.65M
Revenue Per Share
1.09
Gross Profit TTM
0.52M
Debt / Equity
0.00
ROE
-105.23%
Net Debt
-5.17M
ROCE
-84.11%
Diluted EPS TTM
749.08

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -14.03M -59.74M -37.42M -13.42M -3.42M
Net income -14.03M -58.69M -37.41M -13.42M -3.42M
Selling general administrative 7.04M 11.23M 14.77M 9.35M 2.09M
Selling and marketing expenses - - 1.98M - -
Gross profit 0.63M 1.06M -1.14M -0.01M -0.00M
Reconciled depreciation 0.02M 0.73M 0.04M 0.01M 0.00M
Ebit -13.28M -58.33M -15.88M -13.54M -3.42M
Ebitda -13.27M -57.60M -15.84M -13.54M -3.41M
Depreciation and amortization 0.02M 0.73M 0.04M 0.01M 0.00M
Operating income -6.34M -56.49M -15.88M -13.48M -3.42M
Other operating expenses 7.16M 59.01M 15.94M 13.48M 3.42M
Interest expense 0.75M 1.41M 0.67M 0.00M -
Tax provision 0.00M -1.05M -0.01M 0.00M -
Interest income 0.00M 0.00M - - 0.00M
Net interest income -0.75M -1.41M -0.67M 0.00M 0.00M
Income tax expense 0.00M -1.05M -0.01M -0.06M -0.00M
Total revenue 0.82M 2.52M 0.06M 0.00M 0.00M
Total operating expenses 6.98M 57.54M 14.74M 13.48M 3.42M
Cost of revenue 0.18M 1.47M 1.20M 0.01M 0.00M
Total other income expense net -7.69M -3.25M -21.54M 0.06M -0.00M
Net income from continuing ops -14.03M -58.69M -37.41M -13.42M -3.42M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 24.93M 28.18M 88.82M 26.31M 3.08M
Intangible assets - - 25.41M - -
Other current assets 0.40M 0.14M 0.77M 0.47M 0.23M
Total liab 9.16M 18.57M 23.18M 3.92M 1.64M
Total stockholder equity 15.76M 9.61M 58.63M 22.39M 1.45M
Other current liab 7.35M 5.02M 2.20M 2.42M 1.06M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 1.07M 0.00M 0.00M 0.00M
Retained earnings -131.21M -115.68M -56.79M -19.38M -5.96M
Good will 18.55M 27.05M 55.68M 0.00M -
Cash 5.22M 0.65M 4.55M 25.75M 1.93M
Total current liabilities 9.14M 18.29M 17.19M 3.92M 1.64M
Net debt -5.17M 8.80M 5.33M -25.75M -1.93M
Short term debt 0.02M 9.45M 9.69M - -
Short long term debt - 9.33M 9.62M - -
Short long term debt total 0.05M 9.45M 9.89M - -
Other stockholder equity 147.21M 126.95M 48.80M 41.76M 7.40M
Total current assets 6.07M 0.95M 5.84M 26.26M 3.07M
Net receivables 0.30M 0.10M 0.15M 0.04M 0.15M
Long term debt - - 0.12M - -
Inventory 0.15M 0.06M 0.36M 0.00M 0.76M
Accounts payable 1.76M 3.79M 5.30M 1.50M 0.58M
Accumulated other comprehensive income -0.23M -2.72M 2.38M - -
Non currrent assets other 0.23M -0.25M -25.03M 0.04M -
Non current assets total 18.86M 27.23M 82.98M 0.05M 0.01M
Capital lease obligations 0.05M 0.12M 0.15M 0.00M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.03M -8.65M -0.01M -0.00M
Total cashflows from investing activities - -0.03M - - -
Net borrowings -5.78M 3.65M - - -
Total cash from financing activities 14.45M 6.74M 1.04M 32.53M -0.33M
Net income -14.03M -58.69M -37.41M -13.42M -3.42M
Change in cash 4.57M -3.91M -21.20M 23.82M -2.38M
Begin period cash flow 0.65M 4.55M 25.75M 1.93M 4.31M
End period cash flow 5.22M 0.65M 4.55M 25.75M 1.93M
Total cash from operating activities -9.68M -10.50M -13.58M -8.70M -2.04M
Issuance of capital stock 21.94M 3.48M 2.30M 34.87M 0.00M
Depreciation 0.02M 0.73M 0.04M 0.01M 0.00M
Dividends paid 0.41M 0.21M - - -
Change to inventory -0.07M -0.06M -0.32M 0.02M 0.11M
Change to account receivables -0.32M 0.12M -0.06M -0.02M -0.11M
Sale purchase of stock -1.71M -0.00M -0.06M -0.57M 0.00M
Other cashflows from financing activities -0.00M 2.61M -0.21M -1.77M -0.33M
Capital expenditures 0.00M 0.03M 0.06M 0.01M 0.00M
Change in working capital -2.42M -1.54M 1.62M 2.54M 1.21M
Stock based compensation 0.07M 0.44M 0.33M 1.97M 0.13M
Other non cash items 6.68M 49.61M 21.84M 0.26M 0.02M
Free cash flow -9.68M -10.52M -13.64M -8.71M -2.05M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ONCO
Onconetix Inc		 1.46
26.59%		 6.95 - - 4.48 0.21 0.20 -0.47
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Onconetix Inc

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

201 East Fifth Street, Cincinnati, OH, United States, 45202

513 620 4101

https://www.onconetix.com

2

Name Title Year Born
Dr. Ralph Schiess Ph.D. Interim CEO & Chief Science Officer 1979
Mr. Bruce Harmon Chief Financial Officer 1958
Dr. Brian Price Ph.D. Head of Technology Strategy NA
Mr. Frank A. Jaeger M.A., M.B.A. Senior VP of Marketing & Business Development 1970
Mr. Andrew D. Skibo Ph.D. Global Head of Biologics Operations NA
Mr. Theodore Scott Yoho Head of Business Development NA
Dr. Ali I. Fattom Ph.D. Head of Science & Discovery NA
Dr. Jay Newmark M.B.A., M.D. Chief Medical Officer NA
Mr. Christian Bruhlmann Chief Strategy Officer & GM of Europe 1977
Dr. Donald L. Very Jr., Ph.D. Senior VP of Commercial Research & Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…